Keywords
Abstract
Alzheimer kasalligi – surunkali progressiv neyrodegenerativ kasallik bo‘lib, xotira, fikrlash va xulq-atvor buzilishlariga olib keladi. Ushbu maqolada so‘nggi yillarda Alzheimer kasalligini davolash va simptomlarni yengillashtirish bo‘yicha ishlab chiqilgan yangi dori vositalari va terapevtik yondashuvlar tahlil qilinadi. Xususan, amiloid-beta plakklarini tozalovchi monoklonal antitanalar (adukanumab, lekanemab), tau-patologiyaga qarshi modulyatorlar, neyroinflammasiyaga ta’sir qiluvchi vositalar hamda noinvaziv neyrostimulyatsiya usullarining samaradorligi va klinik ahamiyati ko‘rib chiqiladi. Shuningdek, biomarkerlar asosidagi individual terapiya yondashuvlari va sun’iy intellekt yordamida erta diagnostika texnologiyalari haqida ma’lumotlar keltiriladi.
References
1. Cummings, J., et al. (2022). Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
2. FDA News Release (2021). FDA grants accelerated approval for Alzheimer’s drug Aduhelm (aducanumab).
3. van Dyck, C. H., et al. (2023). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 9–21.
4. Long, J. M., & Holtzman, D. M. (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 179(2), 312–339.
5. Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608.
6. Hampel, H., et al. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639–652.
7. Jack, C. R., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.
8. Dubois, B., et al. (2021). Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. The Lancet Neurology, 20(6), 484–496.
9. Dacks, P. A., et al. (2021). Precision medicine approaches to Alzheimer’s disease. Alzheimer's & Dementia, 17(7), 1071–1083.